StreetAlpha.app
Home › Stocks › PGEN

Precigen, Inc. (PGEN)

Healthcare
$4.21
▲ +1.20%
LAST CLOSE · NOV 20

Precigen is a biopharmaceutical company that develops gene medicines for patients with cancer, autoimmune and infectious diseases. It last closed at $4.21 on Nov 20, up 1.20% on the day. The next earnings report for PGEN is expected around Wed, Mar 24, 2027, after the close. For the quarter ended Sep 2026, PGEN reported EPS of $0.08 on revenue of $74.1M, with revenue up 2437.6% from a year ago. Over its last 8 reports the stock moved an average of 11.8% the session after earnings. Over the last 12 months PGEN insiders bought $25K of stock on the open market and sold $44.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is PGEN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PGEN.

Key Stats

Last 12 months
Results
Revenue
$156.9M
Net income
$24.4M
15.6% margin
EPS (diluted)
$0.11
Free cash flow
−$74.3M
−47.4% margin
Valuation
Market cap
$1.5B
358.5M shares
P/E
38.3
Price over 12 month EPS
Price to sales
9.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$15.0M
At Sep 30
Debt
$94.3M
At Sep 30
Shareholder equity
$83.8M
Shares outstanding
358.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $14.3M$14.3MFY2021FY2022: $26.9M$26.9MFY2022FY2023: $6.2M$6.2MFY2023FY2024: $3.9M$3.9MFY2024FY2025: $9.7M$9.7MFY2025

From PGEN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 24
Estimated date · After the close
Reported EPS
$0.08
Quarter ended Sep 2026
Year ago EPS
-$1.06
Same quarter last year
Revenue
$74.1M
+2437.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.06Dec '24Mar 2025: -$0.18Mar '25Jun 2025: -$0.09Jun '25Sep 2025: -$1.06Sep '25Dec 2025: -$0.01Dec '25Mar 2026: -$0.02Mar '26Jun 2026: $0.05Jun '26Sep 2026: $0.08Sep '26Latest $0.08
Revenue by quarter
Mar 2025: $1.3MMar '25Jun 2025: $856,000Jun '25Sep 2025: $2.9MSep '25Dec 2025: $4.6MDec '25Mar 2026: $23.3MMar '26Jun 2026: $55.0MJun '26Sep 2026: $74.1MSep '26Latest $74.1M
How PGEN moved after its last 8 reports
Average move the session after a report ±11.8%
Nov 5, 2026Before the open−16.5%
Aug 4, 2026After the close+5.5%
May 13, 2026After the close+10.8%
Mar 25, 2026After the close+25.5%
Nov 13, 2025After the close+25.6%
May 14, 2025After the close+2.3%
Mar 19, 2025After the close+0.6%
Nov 14, 2024After the close−7.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PGENStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PGEN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PGEN

Technical Analysis

PGEN · as of the Nov 20 close · updated each morning
Turning down, nearing oversold

The stock is 19% below its 20 day and 54% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the swing low (May 27) at $4.11, and the nearest resistance the Pivot R1 at $4.36.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.0%/day
Key levels
$8.9852 week high+113.3%
$6.4850 day average+53.9%
$6.39100 day average+51.8%
$5.27200 day average+25.2%
$5.0220 day average+19.2%
$4.68Swing high (May 28)+11.2%
$4.36Pivot R1+3.6%
$4.21Pivot+0.0%
$4.21Last close
$4.11Swing low (May 27)−2.4%
$4.07Pivot S1−3.3%
$3.0452 week low−27.8%
Indicators
RSI (14)31.96Weak, oversold below 30Neutral
MACD-0.67Below its signal lineBearish
Stochastic15.5Near the bottom of its rangeOversold
ADX (14)29.7Trending down
Williams %R-80.1Oversold below −80, overbought above −20Oversold
CCI (20)-76.0Oversold below −100, overbought above 100Neutral
Rate of change−5.8%Change over 10 sessionsBearish
ATR (14)$0.42Typical daily range, 10.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PGEN

What happened before

See how PGEN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PGEN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PGEN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PGENHow many large options trades hit PGEN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

PGEN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲142 buying vs 73 selling
  • ▲Held by funds +0.8 pts
  • ▲Funds holding +34
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding246212+16.0%
In funds' top 1053+66.7%
Held by funds40.0%39.2%+0.8 pts
New / increased54 / 8836 / 84+18.3%
Reduced / sold out52 / 2145 / 280.0%
Put/call ratio0.061.08−94.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PGEN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PGEN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$25K1 buy · 1 insider
Sold$44.8M18 sales · 7 insiders
12% of the selling was under pre-arranged trading plans.
2025-12 sold $8.8M2026-03 sold $15.8M2026-05 sold $1.1M2026-06 sold $2.3M2026-07 sold $1.7M2026-08 bought $25K2026-08 sold $2.8MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 26Jeffrey B KindlerDirectorSale185,000$7.44$1.4M
Aug 25Phil TennantChief Commercial OfficerSale plan79,166$7.50$594K
Aug 25Rutul R ShahCOOSale plan50,000$7.50$375K
Aug 21Nancy H AgeeDirectorBuy3,411$7.23$25K
Aug 6Rutul R ShahCOOSale plan32,739$6.86$225K
Aug 3Rutul R ShahCOOSale plan33,772$6.50$220K
Every insider buy and sale for PGEN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PGEN insider trades →

From SEC Form 4 filings by PGEN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PGEN is in one of them and how their past PGEN trades turned out.

PGEN in the AI portfolios
Loading…

PGEN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PGEN in an article yet. Here's the latest on the wider market.

PGEN in the news

About Precigen

Precigen is a biopharmaceutical company based in Germantown, Maryland, that develops medicines for patients with hard to treat diseases. Its main focus areas are cancer, autoimmune disorders and infectious diseases. Its approved product, Papzimeos, is an immunotherapy for adults with recurrent respiratory papillomatosis, a rare disease caused by HPV infection. The company also develops cell and gene therapies that are in clinical trials or at earlier research stages.

Headquarters
Germantown, MD
Founded
1998